Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine ...

Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an ...

All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Aura. The gross proceeds from the offering to Aura are expected to be $75.0 million, ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Halozyme Therapeutics (HALO) stock remains under pressure as Morgan Stanley downgrades the company on Medicare price negotiation concerns. Read more here.

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Vertex Pharmaceuticals took a confidence hit as Leerink Partners downgraded the stock from “strong-buy” to a mere “hold,” ...

Leerink Partnrs also issued estimates for Revvity’s Q4 2025 earnings at $1.54 EPS, Q2 2026 earnings at $1.43 EPS, Q4 2026 earnings at $1.70 EPS and FY2026 earnings at $5.68 EPS. Get Revvity alerts: ...

Leerink Partnrs also issued estimates for AbbVie’s Q3 2025 earnings at $3.18 EPS, Q4 2025 earnings at $3.33 EPS, FY2026 earnings at $14.01 EPS, FY2028 earnings at $17.67 EPS and FY2029 earnings ...